PolyPid Ltd (PYPD)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site...

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently  U.S. Commercial...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with...

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the...

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 ...

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities